登录

Minkang Bio Closes ¥150M Pre-IPO Funding Round

作者: Mailman 2020-01-17 17:52
民康生物
http://mycura.cn
企业数据由 动脉橙 提供支持
血糖监测系统产品研发、生产、销售商 | PreIPO | 运营中
中国-天津
2020-01-15
融资金额:RMB¥1.5亿
中国风险投资
查看

According to Yiou.com, Minkang Biological ("Minkang Bio") announced that it has completed a ¥150 million (US$21.8 million) Pre-IPO round of financing, led by China Venture Capital. As Gan Jianmin, founder and chairman of Minkang Bio, said, the proceeds of this financing will be used to upgrade the existing products of comprehensive diabetes detection and build a new production base of about 100 acres for future development and capacity foundation, to make full preparation for the listing.


Minkang Bio has received nearly 250 million yuan in financing in five years, including ¥52.5 million series A financing led by Yuansheng Capital in 2015, and ¥40 million led by Shanshan Venture Capital in 2017.


Minkang Bio was registered in Beijing in June 2010 and relocated to Tianjin in September 2013. The company is engaged in the research and development, production, and sales of the blood glucose monitoring system, glycosylated hemoglobin test system, blood lipids, blood ketone body detection system, and POCT (Point Care of internal Care Testing) products.


Minkang Bio has the international first-class 5000 square meters standardization of 100,000 level GMP production base, 1500 square meters professional research and development center.


After years of research and development, Minkang Bio's technology system of electrochemistry, photochemistry, colloidal gold and immunity has been formed. The company has access to nearly 20 patents and software copyright.


Based on comprehensive diabetes and diabetes complications monitoring system, Minkang Bio has built the diabetes health management Internet platform, providing the remote guidance and disease intervention services, to create a "products - monitoring - diagnosis and treatment" health management system, and achieve early prevention, early detection, and early intervention.


>>>>

About China Venture Capital


China Venture Capital is a professional investment firm mainly engaged in venture capital and fund management, which was initiated by the China National Democratic Construction Association ("CNDCA") in 2000 and shared by members of CNDCA. It is one of the important pioneers in China's venture capital industry.


China Venture Capital manages more than 20 RMB funds. The company's investment covers angel investment, venture capital, equity investment, and industrial mergers & acquisitions. The company focuses on investing in energy conservation and environmental protection, new materials, new energy, high-end manufacturing, rail transit, military aerospace, medicine and medical treatment, the Internet and so on. 

相关赛道 IVD
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

【首发】康沣生物完成数亿元B轮融资,浩悦资本担任独家财务顾问

风再起时,如何应对数字医疗新一轮浪潮?

Coronary Medical Devices Company HS Medical Raises ¥40M in Series Pre-A Round

Wellgrow Techonogy Snags $1.4M in Series A Financing, Led by Green Pine Capital Partners

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany

2020-01-17
下一篇

Tisenc Medical Closes on ¥80M Series B Financing

2020-01-17